CB-181963
| Code | Size | Price |
|---|
| TAR-T30767-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
CB-181963, a new cephalosporin, is an effective antistaphylococcal drug, showing excellent activity against the resistance of MRSA strains to other cephalosporins in planktonic and biofilm cultures.
CAS:
635292-67-0
Formula:
C19H24FN11O5S2
Molecular Weight:
569.59
Purity:
0.98
SMILES:
CN(N=CC1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N/OCF)c1nsc(N)n1)C2=O)C(O)=O)C(=N)N1CCNCC1
References
1. Burall LS, Rodolakis A, Rekiki A, Myers GS, Bavoil PM. Genomic analysis of an attenuated Chlamydia abortus live vaccine strain reveals defects in central metabolism and surface proteins. Infect Immun. 2009 Sep;77(9):4161-7. doi: 10.1128/IAI.00189-09. Epub 2009 Jul 13. PubMed PMID: 19596773; PubMed Central PMCID: PMC2738009.
2. Miller K, Storey C, Stubbings WJ, Hoyle AM, Hobbs JK, Chopra I. Antistaphylococcal activity of the novel cephalosporin CB-181963 (CAB-175). J Antimicrob Chemother. 2005 Apr;55(4):579-82. Epub 2005 Feb 18. PubMed PMID: 15722396.
3. Hoellman DB, Pankuch GA, Appelbaum PC. Antistaphylococcal activity of CB-181963 (CAB-175), an experimental parenteral cephalosporin. Antimicrob Agents Chemother. 2004 Oct;48(10):4037-9. PubMed PMID: 15388474; PubMed Central PMCID: PMC521906.
4. Huang V, Brown WJ, Rybak MJ. In vitro activities of a novel cephalosporin, CB-181963 (CAB-175), against methicillin-susceptible or -resistant Staphylococcus aureus and glycopeptide-intermediate susceptible staphylococci. Antimicrob Agents Chemother. 2004 Jul;48(7):2719-23. PubMed PMID: 15215134; PubMed Central PMCID: PMC434184.